HealthcareFeb 7, 2026

GLP-1 drugs will reshape the food and healthcare industries

Obesity drugs like Ozempic and Wegovy are achieving 15-20% weight loss with strong adherence. As prices fall and insurance coverage expands, adoption could reach 50M+ Americans by 2030, disrupting food, fitness, and medical device sectors.

Signal Strength
Strong

Bull Case

  • +

    Clinical trials show sustained 20%+ weight loss with cardiovascular benefits

    SELECT trial results, NEJM Nov 2023

  • +

    Medicare coverage expansion in 2025 opens 30M+ addressable market

    CMS Final Rule 2025

  • +

    Manufacturing scale-up bringing costs down 40% by 2026

    Novo Nordisk Q4 2024 Earnings Call

Bear Case

  • -

    Long-term side effects still unknown - muscle loss concerns emerging

    JAMA meta-analysis on GLP-1 side effects

  • -

    High discontinuation rates (50%+ stop within 2 years) limit market size

    Blue Cross Blue Shield adherence study

  • -

    Generic competition and oral alternatives could compress pricing by 2027

    Morgan Stanley Pharma Research

Unlock Deeper Insights

Join the waitlist to access 2nd & 3rd order effects when we launch

Related Companies

LLY

Eli Lilly

$650B

Mounjaro/Zepbound franchise, fastest-growing GLP-1

NVO

Novo Nordisk

$450B

Ozempic/Wegovy market leader, 60%+ market share

PFE

Pfizer

$160B

Oral GLP-1 in Phase 3, potential disruptor

K

Kellanova

$22B

Snack food exposure - negative impact from reduced consumption

Key Catalysts

Mar 1, 2025

CMS Medicare Part D GLP-1 coverage begins

Jun 15, 2025

Eli Lilly oral GLP-1 Phase 3 results expected

Nov 1, 2025

Novo Nordisk next-gen weekly injection FDA decision

Disclaimer: For informational purposes only. Not investment advice. ThesisSwipe provides research and analysis but does not recommend any specific investment decisions. Always conduct your own research and consult with a qualified financial advisor before investing.

What's your take?

Your reaction is anonymous and helps us improve our theses

Get Early Access

Hundreds of AI-generated investment theses across 12 categories. Launching soon.

Save This Thesis

Join the waitlist to save theses, build your library, and get notified about new ideas.

Free to use. No credit card required.